Invariant chain peptides enhancing or inhibiting the presentation of antigenic peptides by major histocompatibility complex class II molecules
- PMID: 7614997
- DOI: 10.1002/eji.1830250632
Invariant chain peptides enhancing or inhibiting the presentation of antigenic peptides by major histocompatibility complex class II molecules
Abstract
Two soluble invariant chain (Ii) peptides with overlapping sequences had contrasting effects on the presentation of antigenic peptides by murine Ad, Ak, Ed, and Ek major histocompatibility complex (MHC) class II molecules. Naturally produced class II-associated invariant chain peptides human (h)Ii81-104/murine (m)Ii80-103 inhibited antigen presentation on these MHC class II alleles in a manner consistent with competitive inhibition. The Ii-4 peptides hIi77-92/mIi76-91 enhanced presentation of antigenic peptides on I-E class II alleles by promoting the exchange of peptides at the cell surface. Treatment of antigen-presenting cells (APC) with Ii-4 before the addition of antigenic peptide greatly enhanced subsequent T cell responses, while treatment of APC with Ii-4 after antigenic peptide binding decreased subsequent T cell responses. The hIi81-104 and mIi80-103 peptides inhibited T cell responses in both types of assays. The binding of biotinylated antigenic peptide to MHC class II-transfected L cells, as measured by flow cytometry, was inhibited by mIi80-103 and enhanced by mIi-4. Segments of Ii fragments remaining associated with MHC class II, or released Ii peptides, appear to regulate the formation of stable antigenic peptide/MHC class II complexes either positively or negatively through interactions at or near the antigenic peptide binding site. These findings open a pathway for the design of novel therapeutics based on the structure and function of natural and rationally designed fragments of Ii.
Similar articles
-
Studies on activities of invariant chain peptides on releasing or exchanging of antigenic peptides at human leukocyte antigen-DR1.Arzneimittelforschung. 1999 Sep;49(9):791-9. Arzneimittelforschung. 1999. PMID: 10514908
-
A mutant antigen-presenting cell defective in antigen presentation expresses class II MHC molecules with an altered conformation.J Immunol. 1993 May 15;150(10):4206-17. J Immunol. 1993. PMID: 8482833
-
Biological activity and therapeutic potential of homologs of an Ii peptide which regulates antigenic peptide binding to cell surface MHC class II molecules.Arzneimittelforschung. 1997 Sep;47(9):1069-77. Arzneimittelforschung. 1997. PMID: 9342425
-
Quality control of MHC class II associated peptides by HLA-DM/H2-M.Semin Immunol. 1999 Dec;11(6):391-403. doi: 10.1006/smim.1999.0197. Semin Immunol. 1999. PMID: 10625593 Review.
-
Structure of peptides associated with class I and class II MHC molecules.Annu Rev Immunol. 1994;12:181-207. doi: 10.1146/annurev.iy.12.040194.001145. Annu Rev Immunol. 1994. PMID: 7516668 Review.
Cited by
-
Boosting immune response with the invariant chain segments via association with non-peptide binding region of major histocompatibility complex class II molecules.BMC Immunol. 2012 Sep 27;13:55. doi: 10.1186/1471-2172-13-55. BMC Immunol. 2012. PMID: 23016601 Free PMC article.
-
Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer.Cancer Immunol Immunother. 2004 Jun;53(6):490-6. doi: 10.1007/s00262-003-0463-y. Epub 2004 Jan 22. Cancer Immunol Immunother. 2004. PMID: 14740174 Free PMC article.
-
Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence.Ann Oncol. 2016 Jul;27(7):1241-8. doi: 10.1093/annonc/mdw150. Epub 2016 Mar 30. Ann Oncol. 2016. PMID: 27029708 Free PMC article. Clinical Trial.
-
Design of a ProDer f 1 vaccine delivered by the MHC class II pathway of antigen presentation and analysis of the effectiveness for specific immunotherapy.Int J Clin Exp Pathol. 2014 Jul 15;7(8):4636-44. eCollection 2014. Int J Clin Exp Pathol. 2014. PMID: 25197336 Free PMC article.
-
Resolving multiple protein-peptide binding events: implication for HLA-DQ2 mediated antigen presentation in celiac disease.Chem Asian J. 2012 May;7(5):992-9. doi: 10.1002/asia.201101041. Epub 2012 Mar 12. Chem Asian J. 2012. PMID: 22411856 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials